CTOs on the Move

Respicardia

www.respicardia.com

 
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.respicardia.com
  • 12400 Whitewater Dr Suite 150
    Minnetonka, MN USA 55343
  • Phone: 952.540.4470

Executives

Name Title Contact Details

Funding

Respicardia raised $58.5M on 12/19/2017

Similar Companies

Desjardins Healthcare Group

Desjardins Healthcare Group is a Gloucester, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Diabetes Supply

Advanced Diabetes Supply provides diabetes testing supplies to people nationwide. Our highly trained staff and state of the art technology ensures fast and convenient home delivery anywhere in the country.

Canadian Medical Protective Association

Canadian Medical Protective Association is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NuVera Medical

NuVera Medical, Inc., a portfolio company of Shifamed, LLC., is a privately held company focused on the development of a novel imaging platform for use in a growing number of complex cardiovascular procedures.

Lensar

LENSAR, Inc. is a global leader in next-generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and efficiency while optimizing overall visual outcomes. LENSAR`s proprietary Augmented Reality technology -- reconstructed 3-D imaging, measurement, and guidance system -- offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery, and efficient lens fragmentation that can reduce, and potentially eliminate phaco energy. The LENSAR Laser System also offers the industry`s smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms. The LENSAR Laser System has been cleared by FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only